BioLamina

BioLamina has established itself as a key supplier of specialized extracellular matrix (ECM) proteins for advanced cell culture. Its core technology is the production of full-length, human recombinant laminins, which are critical proteins that form the natural scaffold for cells in the body. These products are designed to improve cell performance, differentiation, and yield, offering researchers and therapy developers a standardized, xeno-free, and clinically compliant alternative to traditional, variable matrices like Matrigel. The company's value proposition centers on enabling reproducible science and scalable cell production for regenerative medicine and cell therapy.

Proprietary platform for producing full-length, human recombinant laminin isoforms. These proteins serve as defined, xeno-free, and biologically relevant cell culture matrices that mimic the natural extracellular environment for stem cells and primary cells.

BioLamina competes in the specialized extracellular matrix market. Its primary competitors are large suppliers like Corning (Matrigel) and Thermo Fisher Scientific, which offer animal-derived and some recombinant products. Its key differentiation is its focus on full-length human laminins, offering superior biological relevance and consistency for demanding applications in stem cell research and cell therapy, where it competes with other niche players like iMatrix (recombinant laminin fragments).